Next Generation Protein Sequencing
Founded in 2021 and headquartered in Berkeley, California, Glyphic Biotechnologies exists to fundamentally rewrite the rules of proteomics. The company is developing Protein Sequencing by Expansion (ProSE™), the first truly de novo high-throughput proteome sequencing technology capable of discriminating all 20 amino acids and post-translational modifications with single-molecule sensitivity. Glyphic's platform leverages spatial expansion of amino acids to enable massively parallel proteome sequencing, unlocking critical first-in-class therapies and deeper insights into biology.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2025
Feb 2024
Apr 2022
Jul 2021
Create a free account to see which investors have funded this company.
Create Free AccountLong-read DNA sequencing company providing advanced systems for complete and accurate genome, tra...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Life science company democratizing access to advanced DNA sequencing tools with high-quality, aff...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
